Natural sciences

Global Hydrogen Storage Market (2019 to 2026) - Size, Share, Outlook and COVID-19 Strategies - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Natural sciences, Sustainable technologies, Hydrogen economy, Emerging technologies, Hydrogen technologies, Energy storage, Hydrogen vehicle, Hydrogen storage, Hydrogen

As the Hydrogen Storage industry shifts, the report presents the emerging market trends, factors driving the Hydrogen Storage market growth, and potential opportunities over the forecast period.

Key Points: 
  • As the Hydrogen Storage industry shifts, the report presents the emerging market trends, factors driving the Hydrogen Storage market growth, and potential opportunities over the forecast period.
  • The trends underpinning the profitability of Hydrogen Storage companies are shifting rapidly, forcing companies to carefully align their strengths in synchronization with Hydrogen Storage industry trends.
  • It presents the strategies being adopted by leading Hydrogen Storage companies, emerging market trends, Hydrogen Storage market drivers, challenges, and potential opportunities to 2026.
  • Further, Hydrogen Storage market revenue and market shares in global industry are forecast across different types of Hydrogen Storage, applications, and end-user segments of Hydrogen Storage and across 18 countries.

Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

Retrieved on: 
Thursday, September 10, 2020
Health, Infectious diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Natural sciences, Proteins, Immunology, Contingent value rights, Corporate finance, Valuation, Ligand, Antibody, xCella Biosciences, Taurus Biosciences, OmniAb®, Ligand Pharmaceuticals

Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs).

Key Points: 
  • Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs).
  • Ligand evaluated multiple public and private platforms to acquire in order to continue the expansion of the OmniAb platform and determined xCella and Taurus represented the best fit and opportunity.
  • Bringing the capabilities and intellectual property of these two companies into Ligand will strengthen our antibody discovery capabilities, in particular our OmniChicken platform.
  • Ligands OmniAb technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies.

Aroma Chemicals Market to Reach USD 8.41 Billion By 2027 | CAGR of 6.2%: Reports and Data

Retrieved on: 
Thursday, September 10, 2020
Olfaction, Physical sciences, Chemistry, Natural sciences, Perfumes, Air freshener, Perfume, Deodorant, Aroma compound, Odor, Terpene

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- The Global Aroma Chemicals Market is projected to reach USD 8.41 billion by 2027.

Key Points: 
  • NEW YORK, Sept. 10, 2020 /PRNewswire/ -- The Global Aroma Chemicals Market is projected to reach USD 8.41 billion by 2027.
  • The market is growing rapidly as the demand for the odorants and fragrant intensifiers are expanding considerably in the global market.
  • Perfumes, body deodorants, air-fresheners, soaps, food-scented chemicals are some of the highly consumed end-use products which add to the aroma ingredients market value appreciably.
  • Chemical compounds such as Esters, terpenes have the most number of applications and hence have the highest demand from the end-users.

Satsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine

Retrieved on: 
Thursday, September 10, 2020
Food and Drug Administration, United States Public Health Service, Medication, Health, Natural sciences, Anticonvulsants, RTT, Migraine, Trevena Inc

Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.

Key Points: 
  • Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.
  • John Kollins, President and Chief Executive Officer of Satsuma commented, We are surprised and disappointed that STS101 did not achieve statistical significance on the co-primary endpoints in our EMERGE trial.
  • The EMERGE study was designed in accordance with FDA recommendations outlined in the FDA Guidance Migraine: Developing Drugs for Acute Treatment, February 2018.
  • Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101.

Global Bis(cyclopentadienyl)magnesium Market (2020 to 2025) - by Manufacturers, Regions, Technology, & Application - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Natural sciences, Bis(cyclopentadienyl)titanium(III) chloride, Chlorides, Magnesium, Cyclopentadienyl

The "Bis(cyclopentadienyl)magnesium Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bis(cyclopentadienyl)magnesium Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
  • This report is a professional and in-depth study on the current state of the global Bis(cyclopentadienyl)magnesium market with a focus on the Chinese market.
  • The global Bis(cyclopentadienyl)magnesium market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Bis(cyclopentadienyl)magnesium market covering all important parameters.

Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

Retrieved on: 
Thursday, September 10, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Articles, Macular degeneration, RTT, Senescence, Pharmacodynamics, Life sciences, Natural sciences, Dry AMD, Gemini Therapeutics

The safety, pharmacokinetics, and pharmacodynamics data from the Phase 1 study supports the advancement of GEM103 to a Phase 2a study.

Key Points: 
  • The safety, pharmacokinetics, and pharmacodynamics data from the Phase 1 study supports the advancement of GEM103 to a Phase 2a study.
  • As in the preceding Phase 1 study, the study will evaluate aqueous humor samples for pharmacokinetics and markers of inflammation.
  • The Phase 1 portion of the study enrolled 12 patients in a genetically screened population with dry AMD and central GA.
  • Gemini Therapeutics is examining many of these genetic variants through CLARITY, its natural history study in people with dry AMD.

Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™

Retrieved on: 
Thursday, September 10, 2020
Biotechnology, Pharmaceutical, Optical, Health, Medication, Pharmaceutical industry, Health, Natural sciences

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for EYSUVIS as a short-term treatment for the signs and symptoms of the disease.

Key Points: 
  • Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for EYSUVIS as a short-term treatment for the signs and symptoms of the disease.
  • The event will be held virtually on Thursday, September 17, 2020, beginning at 8:00 a.m.
  • Additionally, Kala management will present an update on launch planning for EYSUVIS.
  • If approved, Kala expects to launch EYSUVIS before year-end.

Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference

Retrieved on: 
Thursday, September 10, 2020
Natural sciences, Astellas Pharma, Mitsubishi UFJ Financial Group, Chemistry, Pharmaceutical industry in China, Articles, Actinium

NEW YORK, Sept. 10, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 2:00 PM EST.

Key Points: 
  • NEW YORK, Sept. 10, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 2:00 PM EST.
  • The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.
  • Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.
  • Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.

Global Oil and Gas Separator Industry to 2025 - Middle-East and Africa are Expected to Dominate the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Oil, Gas, Energy, Chemistry, Physical sciences, Natural sciences, Industrial equipment, Separator, Petroleum, Gas oil separation plant, Oil sands

Oil and gas separator is a pressurized vessel that is used for the separation of oil, gas, water, sand, salts, and other solid sediments.

Key Points: 
  • Oil and gas separator is a pressurized vessel that is used for the separation of oil, gas, water, sand, salts, and other solid sediments.
  • Hence, owing to the above points, the upstream segment is likely to dominate the oil and gas separator market during the forecast period.
  • Middle-East and Africa, due to its highest crude oil production in the world, held a significant market share in the market.
  • Hence, owing to the above points, Middle-East and Africa are expected to dominate the oil and gas separator market during the forecast period.

Outlook on the Boron Trifluoride Global Market to 2025 - by Manufacturers, Regions, Technology, & Application - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Technology, Chemicals, Plastics, Other Technology, Manufacturing, Chemistry, Physical sciences, Natural sciences, Fluorides, Chemical elements, Industrial gases, Boron compounds, Boron, Trifluoride, Fluorine

The report explores Global and Chinese major players in Boron Trifluoride market.

Key Points: 
  • The report explores Global and Chinese major players in Boron Trifluoride market.
  • The report depicts the global and Chinese total Boron Trifluoride market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
  • The global Boron Trifluoride market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Boron Trifluoride market covering all important parameters.